News & Events about Exscientia Plc.
Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in Orlando, FL. Were excited to further validate Exscientias end-to-end approach of integrating outstanding science with...
Thinking about buying stock in Newmark Group, Exscientia, Pardes Biosciences, Creative Medical Technology, or Somalogic? Thinking about buying stock in Newmark Group, Exscientia, Pardes Biosciences, Creative Medical Technology, or Somalogic? PR Newswire NEW YORK, April 12, 2023 NEW YORK, April 12...
Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States. The compound is in development for immunology & inflammation...
Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first European country. IGNITE-AI is a Phase 1/2 trial studying EXS-21546 ('546), Exscientias A2A receptor antagonist in combination with anti-PD-1 therapy in...